ARTICLE | Company News
Novo in deal for EpiDestiny's hematology candidate
April 5, 2018 10:20 PM UTC
EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million upfront payment and undisclosed milestones, plus royalties.
Last year, EpiDestiny said EPI01 was well tolerated and increased total hemoglobin in a Phase I trial in 25 patients with SCD after eight weeks of treatment. Novo and EpiDestiny will jointly continue development in SCD and beta-thalassemia. EpiDestiny retains rights to develop EPI01 for oncology indications...
BCIQ Company Profiles